Development of a clinically significant ADAMTS13 inhibitor in a patient with hereditary thrombotic thrombocytopenic purpura

Am J Hematol. 2015 Jan;90(1):E22. doi: 10.1002/ajh.23851. Epub 2014 Oct 18.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • ADAM Proteins / antagonists & inhibitors*
  • ADAM Proteins / genetics
  • ADAMTS13 Protein
  • Adult
  • Female
  • Humans
  • Mutation
  • Plasma Exchange* / adverse effects
  • Purpura, Thrombotic Thrombocytopenic* / enzymology
  • Purpura, Thrombotic Thrombocytopenic* / genetics
  • Purpura, Thrombotic Thrombocytopenic* / therapy
  • Treatment Outcome

Substances

  • ADAM Proteins
  • ADAMTS13 Protein
  • ADAMTS13 protein, human